Ann: Positive Results for Flavocide in Initial Field Testing, page-47

Not exactly sure the rationale for this comment given the Pre-IPO round was done at $0.14 and thus those investors would now be sitting on a ~11% loss - however for the sake of making a false claim to build a baseless argument, sure lets call it 100% profit.

With this said there are investors who invested over 18 months prior to listing who came in at $0.05 and therefore are sitting on 100% profit - they are called seed/Series A investors who took all the risk and kept the Company alive when it was trying to fund early MOA testing and Virbac discussions in order for people like you to come in at the IPO and try and make a quick dollar without understanding the longer term vision and milestones.

Just to round off , I went and looked at the share price chart from the first week and sure enough the price ended the first week of trading at $0.24 - $20% up on listing. If this is an 'amateur farce from Day 1' in your book then maybe we should scrap the testing and Management should simply let you invest the remaining cash balance - oh wait, just remembered....they are held accountable to shareholders for providing a factual, measured information to the market.